NCT05485961: An ongoing trial by CSL Behring
This trial is ongoing. It must report results 4 years, 5 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05485961 |
|---|---|
| Title | A Phase 2b / 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 21, 2022 |
| Completion date | Sept. 27, 2029 |
| Required reporting date | Sept. 27, 2030, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |